PortfoliosLab logoPortfoliosLab logo
BIOT.L vs. USPY.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BIOT.L vs. USPY.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) and L&G Cyber Security UCITS ETF USD (Acc) (USPY.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIOT.L achieves a 8.59% return, which is significantly lower than USPY.L's 43.57% return.


BIOT.L

1D
0.07%
1M
6.33%
6M
9.47%
YTD
8.59%
1Y
32.65%
3Y*
10.27%
5Y*
2.89%
10Y*

USPY.L

1D
-1.07%
1M
10.66%
6M
46.46%
YTD
43.57%
1Y
40.35%
3Y*
28.12%
5Y*
12.05%
10Y*
17.00%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIOT.L vs. USPY.L - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BIOT.L
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF
8.59%36.47%-5.31%-9.28%-8.41%-3.60%28.29%13.02%-8.12%
USPY.L
L&G Cyber Security UCITS ETF USD (Acc)
43.57%7.58%17.82%42.25%-32.63%7.68%42.21%29.64%4.65%

Correlation

The correlation between BIOT.L and USPY.L is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.34

Correlation (5Y)
Calculated over the trailing 5-year period

0.47

Correlation (All Time)
Calculated using the full available price history since Jan 18, 2018

0.53

Over the past year, the correlation between BIOT.L and USPY.L has dropped to 0.18 - well below their long-term average of 0.53, suggesting their price drivers have been diverging.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIOT.L vs. USPY.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIOT.L
BIOT.L Risk / Return Rank: 6969
Overall Rank
BIOT.L Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
BIOT.L Sortino Ratio Rank: 6767
Sortino Ratio Rank
BIOT.L Omega Ratio Rank: 5858
Omega Ratio Rank
BIOT.L Calmar Ratio Rank: 8484
Calmar Ratio Rank
BIOT.L Martin Ratio Rank: 7272
Martin Ratio Rank

USPY.L
USPY.L Risk / Return Rank: 5555
Overall Rank
USPY.L Sharpe Ratio Rank: 5656
Sharpe Ratio Rank
USPY.L Sortino Ratio Rank: 5555
Sortino Ratio Rank
USPY.L Omega Ratio Rank: 5757
Omega Ratio Rank
USPY.L Calmar Ratio Rank: 5959
Calmar Ratio Rank
USPY.L Martin Ratio Rank: 4747
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIOT.L vs. USPY.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) and L&G Cyber Security UCITS ETF USD (Acc) (USPY.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BIOT.LUSPY.LDifference
Sharpe ratioReturn per unit of total volatility

+0.19

Sortino ratioReturn per unit of downside risk

+0.30

Omega ratioGain probability vs. loss probability

1.27

1.27

+0.01

Calmar ratioReturn relative to maximum drawdown

3.40

2.22

+1.18

Martin ratioReturn relative to average drawdown

9.73

5.76

+3.97

BIOT.L vs. USPY.L - Sharpe Ratio Comparison

The current BIOT.L Sharpe Ratio is 1.61, which is comparable to the USPY.L Sharpe Ratio of 1.42. The chart below compares the historical Sharpe Ratios of BIOT.L and USPY.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BIOT.L vs. USPY.L - Drawdown Comparison

The maximum BIOT.L drawdown since its inception was -34.44%, smaller than the maximum USPY.L drawdown of -39.35%. Use the drawdown chart below to compare losses from any high point for BIOT.L and USPY.L.


Loading charts...

Drawdown Indicators


BIOT.LUSPY.LDifference

Max Drawdown

Largest peak-to-trough decline

-34.44%

-39.35%

+4.91%

Max Drawdown (1Y)

Largest decline over 1 year

-9.55%

-18.08%

+8.53%

Max Drawdown (3Y)

Largest decline over 3 years

-19.91%

-27.03%

+7.12%

Max Drawdown (5Y)

Largest decline over 5 years

-33.80%

-39.35%

+5.55%

Max Drawdown (10Y)

Largest decline over 10 years

-39.35%

Current Drawdown

Current decline from peak

-5.43%

-4.82%

-0.61%

Average Drawdown

Average peak-to-trough decline

-13.31%

-9.82%

-3.49%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.35%

6.99%

-3.64%

Volatility

BIOT.L vs. USPY.L - Volatility Comparison

The current volatility for L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) is 5.96%, while L&G Cyber Security UCITS ETF USD (Acc) (USPY.L) has a volatility of 11.35%. This indicates that BIOT.L experiences smaller price fluctuations and is considered to be less risky than USPY.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIOT.LUSPY.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.96%

11.35%

-5.39%

Volatility (6M)

Calculated over the trailing 6-month period

15.54%

25.32%

-9.78%

Volatility (1Y)

Calculated over the trailing 1-year period

20.19%

28.28%

-8.09%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

18.62%

26.09%

-7.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

19.50%

23.57%

-4.07%

BIOT.L vs. USPY.L - Expense Ratio Comparison

BIOT.L has a 0.49% expense ratio, which is lower than USPY.L's 0.69% expense ratio.


Dividends

BIOT.L vs. USPY.L - Dividend Comparison

Neither BIOT.L nor USPY.L has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


BIOT.L and USPY.L have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BIOT.L is cheaper at 0.49% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BIOT.L is cheaper with a 0.49% expense ratio, compared with 0.69% for USPY.L.

BIOT.L is categorized as Health & Biotech Equities, while USPY.L is Technology Equities. BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return, while USPY.L tracks Nasdaq ISE Cyber Security UCITS Net Total Return Index. Their fees differ too: 0.49% for BIOT.L and 0.69% for USPY.L.

Portfolio Optimizer

Find the right allocation for BIOT.L and USPY.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer